Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Serenex logo — Pioneering innovative treatments in oncology and beyond thro...

Serenex

Pioneering innovative treatments in oncology and beyond through a robust Hsp90 inhibitor platform and advanced therapy for oral mucositis.

Founded 2000 Series D Total: $81.00M Biotechnology, Health Care

General Information

Company Name Serenex
Founded Year 2000
Industries Biotechnology, Health Care
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Serenex. To contact Serenex, visit serenex.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Serenex compare?

A PDF of Serenex and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Serenex soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Serenex

Serenex is a biotechnology and healthcare company that has been pioneering innovative treatments in oncology and beyond since its founding in 2000. Specializing in medical drug discovery and development, Serenex focuses on an Hsp90 product platform, offering a range of small molecule Hsp90 inhibitors for various conditions, including cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative conditions such as Alzheimer's. One of its notable developments is SNX-1012, a treatment for oral mucositis in patients with solid tumors. In 28 June 2007, Serenex received a significant $26.00M Series D investment from Intersouth Partners, Pac-Link, Lilly Ventures, Takeda Pharma, Seaflower Ventures, Pearl Street Venture Funds, L. P., Cornel Capital Partners, Mediphase Venture Partners, and Mitsubishi International Corporation (MIC). The company's dedication to cutting-edge medical advancements in oncology and its successful acquisition by Pfizer in 2008, reflect its potential and the recognition it has garnered from industry leaders.

Business keywords: Medical Drug Discovery, Oncology, Hsp90 Inhibitor, Cancer Treatment, Inflammatory Diseases, Fungal Infection, Viral Diseases, Neurodegenerative Conditions, Alzheimer's, SNX-1012, Oral Mucositis, Solid Tumors, Pfizer, Acquisition, Biopharmaceutical

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $26.00M 9
Intersouth Partners Pac-Link Lilly Ventures
Intersouth Partners, Pac-Link +7
28 Jun 2007
Series C $30.00M 1
Takeda Pharma
Takeda Pharma
06 Oct 2005
Venture Round $8.00M -
30 Jul 2004
Series B $15.00M -
20 Aug 2002
Series A $2.00M -
01 Jun 2001

Serenex Alternatives & Competitors

View All Alternatives
Serenex vs
Synta Pharmaceuticals
Synta Pharmaceuticals

Innovating patient care with advanced small molecule therapies for severe medical conditions, includ...

Post-IPO Equity
Biotechnology, Health Care
Serenex vs
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. United States

VCP/p97 Inhibitors for Oncology and Neurodegenerative Diseases

Series C
3 employees
Biopharma, Biotechnology
Serenex vs
Chromis Therapeutics
Chromis Therapeutics United States

Chromis Therapeutics, Inc. is a San Diego-based biopharmaceutical company, focused on the developmen...

Seed
51-200 employees
Biotechnology, Health Care
View all alternatives

FAQ About Serenex

Pioneering innovative treatments in oncology and beyond through a robust Hsp90 inhibitor platform and advanced therapy for oral mucositis.
Serenex was founded in 2000.
Serenex operates in Biotechnology and Health Care. Its work centres on Medical Drug Discovery, Oncology, Hsp90 Inhibitor and Cancer Treatment.
Serenex has completed 5 funding rounds, raising a total of $81.00M. The latest funding stage is Series D.
Top alternatives and competitors to Serenex include Synta Pharmaceuticals, Cleave Therapeutics, Inc., Chromis Therapeutics, Nereus Pharmaceuticals, Tarveda Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Serenex and Synta Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Serenex, https://bouncewatch.com/company/serenex, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes